2023
VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis.
Kim S, Adams T, Hu Q, Shin H, Chae G, Lee S, Sharma L, Kwon H, Lee F, Park H, Huh W, Manning E, Kaminski N, Sauler M, Chen L, Song J, Kim T, Kang M. VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. American Journal Of Respiratory Cell And Molecular Biology 2023, 69: 22-33. PMID: 36450109, PMCID: PMC10324045, DOI: 10.1165/rcmb.2022-0219oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisImmune regulatorsTherapeutic potentialHuman idiopathic pulmonary fibrosisCrucial immune regulatorsNovel immune regulatorPulmonary fibrosis micePulmonary fibrosis modelNovel therapeutic targetRole of VISTAWild-type littermatesMonocyte-derived macrophagesT lymphocyte lineageVISTA expressionIPF treatmentAntibody treatmentImmune landscapeFibrotic mediatorsLung fibrosisFibrosis miceInflammatory responseFibrosis modelMyeloid populationsTherapeutic target
2021
Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
Kato K, Shin YJ, Palumbo S, Papageorgiou I, Hahn S, Irish JD, Rounseville SP, Krafty RT, Wollin L, Sauler M, Hecker L. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. European Respiratory Journal 2021, 58: 2100759. PMID: 34531276, PMCID: PMC8613836, DOI: 10.1183/13993003.00759-2021.Peer-Reviewed Original ResearchConceptsEfficacy of nintedanibIdiopathic pulmonary fibrosisAged miceLung fibrosisPulmonary fibrosisElderly patientsLung functionPre-clinical efficacy studiesAged animal modelsIPF clinical trialsVital capacity declineAverage patient ageVehicle-treated miceVehicle-treated groupEffect of nintedanibSeverity of fibrosisDevelopment of fibrosisTotal lung collagenSimilar extentNintedanib treatmentLung injuryPatient ageIPF diagnosisClinical efficacyFibrosis severity